16.04.2014 • News

K+S Potash Canada and Pacific Coast to Build Terminal

Pacific Coast Terminals (PCT) and K+S Potash Canada have signed an exclusive, long-term contract for the handling and storage of potash products from the latter company's Legacy mine site.

As part of the deal, the partners will build a new handling facility at PCT's bulk handling terminal in Port Moody, British Columbia. Potash products arriving by rail from the Saskatchewan-based Legacy mine will be unloaded and stored on site and loaded to vessels destined for K+S Group's international clients.

K+S Potash Canada and PCT said they are forming this longstanding partnership to ensure that the transport of the Legacy potash products to international clients is handled with high quality standards, state-of-the-art technology and in a manner that is both secure and competitive. Commissioning and mechanical completion of the new facility are planned for the fall of 2016.

The construction program will include infrastructure, a new railcar unloading station, new covered conveyor systems, systems to control dust emissions and a new storage warehouse. It will start immediately after the required permits from the authorities are issued. Additionally, dredging of the Burrard Inlet will deepen the shipping channel to allow improved vessel navigation and vessel transit windows.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read